Q-omics provides the consensus-scored RPS24P12 profile across patient tissues and cancer cell-line models. RPS24P12 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS24P12 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, RPS24P12 RNA expression shows 11,151 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, KIRP, and ESCA as cancer lineages where RPS24P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS24P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS24P12 survival associations across molecular data types. RPS24P12 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS24P12 RNA expression–survival associations across cancer types. High RPS24P12 expression shows unfavorable associations in ACC, STAD, READ and KIRC, but favorable associations in SKCM and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS24P12 RNA expression.
This table summarizes RPS24P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPS24P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS24P12 shows lower tumor expression in KIRP and higher tumor expression in BRCA, BLCA, CHOL, LIHC and THCA. The KIRP box plot shows higher RPS24P12 RNA expression in normal versus tumor tissue (log2 FC = −0.228, t-test p < 0.001).
This table shows molecular features associated with RPS24P12 in patient tissues and cancer cell lines. In patient samples, RPS24P12 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
